目的研究膀胱癌中,RASSF2A、NORE1A基因启动子甲基化状态在肿瘤发生发展中的作用。方法采用甲基化特异性PCR(methylation specific PCR,MSP)技术检测54例膀胱癌组织及其相应癌周正常组织RASSF2A、NORE1A基因启动子甲基化状态。结果(1)RA...目的研究膀胱癌中,RASSF2A、NORE1A基因启动子甲基化状态在肿瘤发生发展中的作用。方法采用甲基化特异性PCR(methylation specific PCR,MSP)技术检测54例膀胱癌组织及其相应癌周正常组织RASSF2A、NORE1A基因启动子甲基化状态。结果(1)RASSF2A检出率仅为2/54,NORE1A仅为0/54;(2)相应癌周正常组织和3例正常膀胱组织均未发现该基因高甲基化改变;(3)甲基化状态与膀胱癌临床病理参数无明显相关性。结论RASSF2A、NORE1A在膀胱肿瘤中的甲基化率较低,并不适合进行临床筛查。展开更多
Loss of the RASSF2A expression induced by methylation-mediated silencing has been reported in several human cancers, but the methylation status of RASSF2A in hepatocellular carcinoma （HCC） is rarely studied so far. ...Loss of the RASSF2A expression induced by methylation-mediated silencing has been reported in several human cancers, but the methylation status of RASSF2A in hepatocellular carcinoma （HCC） is rarely studied so far. In this study, we investigated the RASSF2A expression and its methylation status in a cohort of 45 hepatitis B virus-associated HCC tissues and their adjacent non-carcinoma tissues by using RT-PCR and MS-PCR. Promoter methylation of RASSF2A was found in 31 （68.9%） out of 45 HCC tissues and 12 （40%） out of 30 adjacent normal tissues, respectively （P〈0.05）. The methylation status of PASSF2A was closely associated with the loss of RASSF2A expression and elevated serum α-fetoprotein level, but not significantly with clinical stage, hepatic fibrosis and K-ras mutation. It was concluded that aberrant methylation of the RASSF2A gene with the subsequent loss of RASSF2A expression plays an important role in the pathogenesis of HCC.展开更多
文摘目的研究膀胱癌中,RASSF2A、NORE1A基因启动子甲基化状态在肿瘤发生发展中的作用。方法采用甲基化特异性PCR(methylation specific PCR,MSP)技术检测54例膀胱癌组织及其相应癌周正常组织RASSF2A、NORE1A基因启动子甲基化状态。结果(1)RASSF2A检出率仅为2/54,NORE1A仅为0/54;(2)相应癌周正常组织和3例正常膀胱组织均未发现该基因高甲基化改变;(3)甲基化状态与膀胱癌临床病理参数无明显相关性。结论RASSF2A、NORE1A在膀胱肿瘤中的甲基化率较低,并不适合进行临床筛查。
文摘Loss of the RASSF2A expression induced by methylation-mediated silencing has been reported in several human cancers, but the methylation status of RASSF2A in hepatocellular carcinoma （HCC） is rarely studied so far. In this study, we investigated the RASSF2A expression and its methylation status in a cohort of 45 hepatitis B virus-associated HCC tissues and their adjacent non-carcinoma tissues by using RT-PCR and MS-PCR. Promoter methylation of RASSF2A was found in 31 （68.9%） out of 45 HCC tissues and 12 （40%） out of 30 adjacent normal tissues, respectively （P〈0.05）. The methylation status of PASSF2A was closely associated with the loss of RASSF2A expression and elevated serum α-fetoprotein level, but not significantly with clinical stage, hepatic fibrosis and K-ras mutation. It was concluded that aberrant methylation of the RASSF2A gene with the subsequent loss of RASSF2A expression plays an important role in the pathogenesis of HCC.
